Another example is AHI, who dual listed on the NASDAQ while remaining on the ASX.
Prices not quite the same but it is now delisted from NASDAQ and was upwards of $1.40 on the ASX and is now 9c and has been in suspension for over 6 months, maybe a year.
Same deal as Brainchip, it had tons of partnerships, what appeared to be a solid board of directors, absolutely no revenue. Got absolutely mauled because it didn't manage to convert those partnerships to revenue. We are in the same position right now, albeit better placed to succeed.
It was my first ever investment at $2,500 and ended up selling all of my shares for $400.
Similarly to Brainchip's ride up to $2.34, I had the opportunity to sell AHI at circa 6x but chose not to because things were looking promising and ended up getting completely fucked

.
Paid a $2,100 lesson but unfortunately didn't learn that lesson until well after Brainchip's slide down from $2.34 otherwise I probably would have realized selling at +$2 was the right move. Hindsight!
I am still as positive as ever on Brainchip's long term value so am not planning to sell any shares, but from experience, fully agree with you on the risks of listing on the NASDAQ too early.
We need more IP licences and preferably royalties rolling in to extract as much value with limited dilution on listing with the NASDAQ or another exchange.
Dual listing is expensive and hopefully not the route they go.
I just hope they show progress to get the share price well up before the redomicile as Aus Super will force my Brainchip shares to be sold so I will lose a significant portion of my holdings (circa 80%). It therefore needs to be at a much higher price than today so that I and other industry fund shareholders make some money on the shares we do lose. Alternatively, share price much higher results in having the value sitting there to make it worthwhile setting up and reinvesting via a SMSF.
Plenty of shareholders are in the same boat as me with their shares being held in an industry fund. It is going to be a real problem for a lot of Australian investors.